Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Deucravacitinib

FDA-approved product (tablet, oral), marketed as Sotyktu.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Deucravacitinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Psoriasis
  • Psoriasis vulgaris

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Janus-associated kinase (jak) inhibitors
FDA pharmacologic class
Tyrosine Kinase 2 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Deucravacitinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Deucravacitinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

    NCT07791199 · start 2026-12-31

    Registered record
    Registry ID
    NCT07791199
    Conditions
    Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis
    Interventions
    Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2030-10-31
    Enrolment
    2,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis
    InterventionDeucravacitinib
    PhasePhase 3
    Registry statusNot yet recruiting

  • Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease

    NCT07280702 · start 2026-06-16

    Registered record
    Registry ID
    NCT07280702
    Conditions
    Psoriatic Arthritis (PsA)
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-06-16
    Completion
    2027-12-15
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriatic Arthritis (PsA)
    InterventionDeucravacitinib; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

    NCT07335796 · start 2026-01-09

    Registered record
    Registry ID
    NCT07335796
    Conditions
    Prostate Cancer
    Interventions
    BMS-986165; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2026-01-09
    Completion
    2030-01-09
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionBMS-986165; Degarelix
    PhasePhase 2
    Registry statusActive not recruiting

  • A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

    NCT06979453 · start 2025-12-03

    Registered record
    Registry ID
    NCT06979453
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-12-03
    Completion
    2034-08-12
    Enrolment
    366

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies

    NCT07564271 · start 2025-10-05

    Registered record
    Registry ID
    NCT07564271
    Conditions
    Idiopathic Inflammatory Myopathies (IIMs)
    Interventions
    Deucravacitinib 6mg po qd
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2025-10-05
    Completion
    2026-10-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Inflammatory Myopathies (IIMs)
    InterventionDeucravacitinib 6mg po qd
    PhaseNot recorded
    Registry statusWithdrawn

  • Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

    NCT07116967 · start 2025-09-22

    Registered record
    Registry ID
    NCT07116967
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib; Ustekinumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-09-22
    Completion
    2031-01-16
    Enrolment
    3,040

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib; Ustekinumab
    PhasePhase 3
    Registry statusRecruiting

  • Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

    NCT07256015 · start 2025-08-05

    Registered record
    Registry ID
    NCT07256015
    Conditions
    Psoriasis
    Interventions
    Deucravacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-08-05
    Completion
    2027-08-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDeucravacitinib
    PhaseNot recorded
    Registry statusRecruiting

  • SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

    NCT07021495 · start 2025-07-29

    Registered record
    Registry ID
    NCT07021495
    Conditions
    Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD); CTCL/ Mycosis Fungoides
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-07-29
    Completion
    2029-12-31
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa (HS); Psoriasis (PsO); Atopic Dermatitis (AD) +1 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis

    NCT07013838 · start 2025-06-15

    Registered record
    Registry ID
    NCT07013838
    Conditions
    Takayasu Arteritis (TAK)
    Interventions
    Deucravacitinib; Adalimumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-06-15
    Completion
    2028-03-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTakayasu Arteritis (TAK)
    InterventionDeucravacitinib; Adalimumab
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Assess Deucravacitinib Safety in Pregnancy

    NCT07017699 · start 2025-03-21

    Registered record
    Registry ID
    NCT07017699
    Conditions
    Psoriasis (PsO)
    Interventions
    Deucravacitinib; Other systemic treatments for PsO
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-03-21
    Completion
    2029-02-28
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis (PsO)
    InterventionDeucravacitinib; Other systemic treatments for PsO
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

    NCT06869551 · start 2025-03-13

    Registered record
    Registry ID
    NCT06869551
    Conditions
    Juvenile Psoriatic Arthritis
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-03-13
    Completion
    2031-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Psoriatic Arthritis
    InterventionDeucravacitinib; Placebo
    PhasePhase 3
    Registry statusRecruiting

  • A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)

    NCT06701513 · start 2025-01-29

    Registered record
    Registry ID
    NCT06701513
    Conditions
    Psoriasis
    Interventions
    Deucravacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-01-29
    Completion
    2028-04-30
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionDeucravacitinib
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Evaluate the Bioequivalence Between Immediate Release Tablets and Minitablets of Deucravacitinib (BMS-986165), and the Effect of Food and pH on the Drug Levels of the Minitablets in Healthy Adults

    NCT06851871 · start 2025-01-23

    Registered record
    Registry ID
    NCT06851871
    Conditions
    Healthy Participants
    Interventions
    Deucravacitinib; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-01-23
    Completion
    2025-04-04
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionDeucravacitinib; Famotidine
    PhasePhase 1
    Registry statusCompleted

  • A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in China

    NCT06512337 · start 2025-01-20

    Registered record
    Registry ID
    NCT06512337
    Conditions
    Plaque Psoriasis
    Interventions
    Deucravacitinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-01-20
    Completion
    2027-03-11
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPlaque Psoriasis
    InterventionDeucravacitinib
    PhaseNot recorded
    Registry statusActive not recruiting

  • Deucravacitinib Rosacea

    NCT06532136 · start 2024-11

    Registered record
    Registry ID
    NCT06532136
    Conditions
    Papulopustular Rosacea
    Interventions
    Deucravacitinib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-11
    Completion
    2026-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPapulopustular Rosacea
    InterventionDeucravacitinib; Placebo
    PhasePhase 2
    Registry statusWithdrawn